Cargando…

Inhibition of Bruton's Tyrosine Kinase Alleviates Monocrotaline-Induced Pulmonary Arterial Hypertension by Modulating Macrophage Polarization

Macrophage accumulation and activation contribute to the development of pulmonary arterial hypertension (PAH), while Bruton's tyrosine kinase (BTK) is an important regulator for the activation and polarization of macrophage. However, the role of BTK in PAH remains unknown. In the present study,...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yu, Min, Wu, Xuecheng, Peng, Liyao, Yang, Mingxia, Zhou, Hong, Xu, Jian, Wang, Jingjing, Wang, Hong, Xie, Weiping, Kong, Hui
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi 2022
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9444460/ https://www.ncbi.nlm.nih.gov/pubmed/36071873 http://dx.doi.org/10.1155/2022/6526036

Ejemplares similares

Paeoniflorin attenuates monocrotaline-induced pulmonary arterial hypertension in rats by suppressing TAK1-MAPK/NF-κB pathways
por: Yu, Min, et al.
Publicado: (2022)

Second-generation inhibitors of Bruton tyrosine kinase
por: Wu, Jingjing, et al.
Publicado: (2016)

Regulatory Phosphorylation of Ikaros by Bruton's Tyrosine Kinase
por: Ma, Hong, et al.
Publicado: (2013)

Bruton's tyrosine kinase: oncotarget in myeloma
por: Tai, Yu-Tzu, et al.
Publicado: (2012)

Editorial: Targeting Bruton Tyrosine Kinase
por: Brunner, Cornelia, et al.
Publicado: (2022)

Targeting Bruton’s Tyrosine Kinase in CLL
por: Ahn, Inhye E., et al.
Publicado: (2021)

Bruton’s Tyrosine Kinase and Its Isoforms in Cancer
por: Wang, Xianhui, et al.
Publicado: (2021)

Inhibition of Shp2 ameliorates monocrotaline-induced pulmonary arterial hypertension in rats
por: Cheng, Yusheng, et al.
Publicado: (2018)

Bruton’s Tyrosine Kinase Targeting in Multiple Myeloma
por: Von Suskil, Max, et al.
Publicado: (2021)

Bruton’s Tyrosine Kinase Inhibition in Multiple Sclerosis
por: Schneider, Raphael, et al.
Publicado: (2022)

Bruton tyrosine kinase inhibitors for multiple sclerosis
por: Krämer, Julia, et al.
Publicado: (2023)

The highly selective Bruton tyrosine kinase inhibitor acalabrutinib leaves macrophage phagocytosis intact
por: Pinney, Jonathan J., et al.
Publicado: (2022)

Bruton tyrosine kinase inhibitor ONO/GS-4059: from bench to bedside
por: Wu, Jingjing, et al.
Publicado: (2016)

Role of Bruton's Tyrosine Kinase in B Cell Development
por: Maas, Alex, et al.
Publicado: (2001)

Novel Bruton’s tyrosine kinase inhibitors currently in development
por: D’Cruz, Osmond J, et al.
Publicado: (2013)

Role of Bruton’s tyrosine kinase in B cells and malignancies
por: Pal Singh, Simar, et al.
Publicado: (2018)

Bruton’s Tyrosine Kinase Inhibition Promotes Myelin Repair
por: Martin, Elodie, et al.
Publicado: (2020)

Bruton’s Tyrosine Kinase Inhibition for the Treatment of Rheumatoid Arthritis
por: Arneson, Laura C, et al.
Publicado: (2021)

Targeting Bruton’s Tyrosine Kinase in Inflammatory and Autoimmune Pathologies
por: Neys, Stefan F. H., et al.
Publicado: (2021)

Editorial: New Insights on Bruton’s Tyrosine Kinase Inhibitors
por: Smith, C. I. Edvard, et al.
Publicado: (2021)

The Use of Bruton Tyrosine Kinase Inhibitors in Waldenström’s Macroglobulinemia
por: Khan, Abdullah Mohammad
Publicado: (2022)

The Use of Bruton Tyrosine Kinase Inhibitors in Waldenström’s Macroglobulinemia
por: Ababneh, Obada, et al.
Publicado: (2022)

Bruton tyrosine kinase inhibitors in the management of Waldenström macroglobulinemia
por: Castillo, Jorge J., et al.
Publicado: (2023)

Bruton’s tyrosine kinase inhibitors in the treatment of multiple sclerosis
por: Shulga, Olga, et al.
Publicado: (2023)

Structural mechanism for Bruton’s tyrosine kinase activation at the cell membrane
por: Wang, Qi, et al.
Publicado: (2019)

Targeting Spleen Tyrosine Kinase-Bruton's Tyrosine Kinase Axis for Immunologically Mediated Glomerulonephritis
por: Chen, Jin-Shuen, et al.
Publicado: (2014)

The Bruton's tyrosine kinase inhibitor ibrutinib exerts immunomodulatory effects through regulation of tumor-infiltrating macrophages
por: Ping, Lingyan, et al.
Publicado: (2017)

Inhibitors targeting Bruton’s tyrosine kinase in cancers: drug development advances
por: Wen, Tingyu, et al.
Publicado: (2020)

Bruton's Tyrosine Kinase Is Essential for Human B Cell Tolerance
por: Ng, Yen-Shing, et al.
Publicado: (2004)

Bruton’s Tyrosine Kinase: An Emerging Key Player in Innate Immunity
por: Weber, Alexander N. R., et al.
Publicado: (2017)

Role of Bruton’s Tyrosine Kinase in Stage III Colorectal Cancer
por: Basile, Debora, et al.
Publicado: (2019)

Correction to: Role of Bruton’s tyrosine kinase in B cells and malignancies
por: Pal Singh, Simar, et al.
Publicado: (2019)

Inhibition of Bruton tyrosine kinase in patients with severe COVID-19
por: Roschewski, Mark, et al.
Publicado: (2020)

The Use of Bruton’s Tyrosine Kinase Inhibitors to Treat Allergic Disorders
por: Dispenza, Melanie C.
Publicado: (2021)

Autoinhibition of Bruton's tyrosine kinase (Btk) and activation by soluble inositol hexakisphosphate
por: Wang, Qi, et al.
Publicado: (2015)

Ibrutinib, a Bruton’s tyrosine kinase inhibitor, exhibits antitumoral activity and induces autophagy in glioblastoma
por: Wang, Jin, et al.
Publicado: (2017)

Bruton’s tyrosine kinase regulates gut immune homeostasis through attenuating Th1 response
por: Guan, Di, et al.
Publicado: (2021)

The Bruton’s Tyrosine Kinase Inhibitor Ibrutinib Impairs the Vascular Development of Zebrafish Larvae
por: Wang, Kun, et al.
Publicado: (2021)

Enhanced Bruton’s tyrosine kinase activity in the kidney of patients with IgA nephropathy
por: Wei, Jie, et al.
Publicado: (2021)

Bruton tyrosine kinase inhibitors in B-cell lymphoma: beyond the antitumour effect
por: Wang, Haoran, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_lnp15krhtqdq3g1gq5ca92gt5f